

A Randomized Controlled Pilot Study Evaluating the Safety and Efficacy of Nifuroxazide in Patients with Ulcerative Colitis

Single centre, randomized placebo-controlled trial.
Patients with mild to moderate ulcerative colitis were randomized to mesalazine 1 gr three times daily and nifuroxazide or mesalazine 1gr t.i.d + placebo for six months.

Primary endpoint: Change in partial Mayo score (PMS)

Results: N=50

- At 6 months nifuroxazide group demonstrated greater improvements in PMS reduction, $p=0.0005$.

Conclusion:

Co-administration of nifuroxazide with mesalamine improved clinical outcomes, including higher response and remission rates, reduced inflammation by reducing IL-6/STAT3, and enhanced quality of life in patients with UC, compared to mesalamine alone.

At 6 months

